AlphaGenome

The platform processes DNA sequences to predict how regulatory elements promoters, enhancers, silencers, and insulators control gene expression across different cell types and developmental stages, enabling researchers to understand the regulatory logic of the genome at resolution and scale that experimental approaches alone cannot achieve.

Variant effect prediction analyzes genetic variants (SNPs, insertions, deletions, structural variants) to predict their functional consequences on gene expression, splicing, and regulatory interactions critical capabilities for interpreting the genetic variants identified in disease association studies and clinical sequencing.

The platform's cell-type-specific predictions account for the fact that the same genomic sequence functions differently in neurons, hepatocytes, cardiomyocytes, and other cell types due to cell-type-specific transcription factor binding and chromatin accessibility, enabling tissue-context-aware interpretation of regulatory variants.

Computational biologists studying gene regulation, clinical researchers interpreting disease-associated variants identified in genome-wide association studies, pharmaceutical scientists identifying therapeutic targets based on regulatory genome function, and biotech companies building genomic medicine platforms use AlphaGenome to extend AI-enabled insights from protein structure into the regulatory genome the next frontier in understanding how the genome encodes both the blueprints for biological molecules and the regulatory instructions that orchestrate their expression across the complexity of human biology.